Lynch & Associates’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Lynch & Associates’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-900	Closed	-$2K	–	96
2019 Q1	$2K	Hold	900	–	–	﹤0.01%	94
2018 Q4	$2K	Hold	900	–	–	﹤0.01%	91
2018 Q3	$4K	Hold	900	–	–	﹤0.01%	98
2018 Q2	$4K	Hold	900	–	–	﹤0.01%	95
2018 Q1	$6K	Hold	900	–	–	﹤0.01%	97
2017 Q4	$6K	Hold	900	–	–	﹤0.01%	95
2017 Q3	$7K	Hold	900	–	–	﹤0.01%	94
2017 Q2	$9K	Hold	900	–	–	﹤0.01%	100
2017 Q1	$10K	Hold	900	–	–	﹤0.01%	99
2016 Q4	$11K	Hold	900	–	–	﹤0.01%	101
2016 Q3	$16K	Hold	900	–	–	0.01%	107
2016 Q2	$10K	Hold	900	–	–	﹤0.01%	109
2016 Q1	$17K	Hold	900	–	–	0.01%	109
2015 Q4	$24K	Hold	900	–	–	0.01%	106
2015 Q3	$41K	Hold	900	–	–	0.02%	103
2015 Q2	$29K	Hold	900	–	–	0.02%	106
2015 Q1	$29K	Hold	900	–	–	0.02%	104
2014 Q4	$34K	Hold	900	–	–	0.02%	95
2014 Q3	$24K	Hold	900	–	–	0.01%	95
2014 Q2	$27K	Hold	900	–	–	0.02%	89
2014 Q1	$33K	Hold	900	–	–	0.02%	94
2013 Q4	$37K	Hold	900	–	–	0.02%	93
2013 Q3	$48K	Hold	900	–	–	0.03%	94
2013 Q2	$48K	Buy	+900	New	+$44.9K	0.03%	95

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lynch & Associates's NAVB Position: Q2 2019 in Review

Lynch & Associates sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 900 shares — an estimated $2K sold.

Lynch & Associates first reported a position in NAVB in Q2 2013 and held it in 24 quarters. The position peaked at $48K in Q3 2013. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

Lynch & Associates reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Lynch & Associates sold 900 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $2K.
Lynch & Associates first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 24 quarters.
Lynch & Associates's Navidea Biopharmaceuticals Inc. position peaked at $48K in Q3 2013.
27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Lynch & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.